The project 'Artificial intelligence algorithms for the screening of cerebral amyloidosis through magnetic resonance imaging in clinical trials of the preclinical phase of Alzheimer's' has received a grant EIT Digital 2021, endowed with 345,000 euros.
The Neuroimaging Research Group of the BarcelonaBeta Brain Research Center (BBRC), led by Dr. Juan Domingo Gispert, has designed a system capable of automatically predicting the presence of abnormal levels of biomarkers of Alzheimer's disease in the brains of individuals without cognitive impairment, by analyzing data derived from magnetic resonance imaging.
The aim of the project is to develop a technology based on artificial intelligence algorithms in magnetic resonance imaging as a tool for preselection of participants in clinical trials of Alzheimer's disease. The use of this new technology would save up to 40 percent the cost of recruiting clinical trials, reducing by 63% the number of tests that are currently performed, and which are invasive, expensive and little accessible. In this way, the technological solution will be associated with savings of 15 million euros per clinical trial.
The project has the collaboration of General Electric (GE) and Genesis Biomed, and has also received funding from the CaixaImpulse program of the "la Caixa" Foundation. The EIT Digital call is aimed at entrepreneurial projects that plan to create a startup or product of digital technology (Innovation Factory), or to offer education programs in digital entrepreneurial technology (Entrepreneurial Academy). The European Institute of Innovation and Technology (EIT) is a European Commission technology project to promote excellence in research, innovation and higher education in European Union member countries.